495 episodios
From Montreal: Congruence Therapeutics uses computational discovery to develop novel small molecule correctors and allosteric modulators - its lead program is for a high profile genetic obesity target
06/11/2026 | 9 minFounder & CEO Clarissa Desjardins describes Congruence's Revenir product engine and walks us through programs that include MC4R deficient obesity, which is in the clinic, alpha-1 antitrypsin deficienty, and Parkinson's.Oxford based Alethio Therapeutics unveiled a $90M Series A today to advance its therapies for myeloproliferative neoplasms, and also announced for the first time that ATX-011's target will be G6B
05/11/2026 | 14 minCEO Rohit Batta describes the unmet need in myeloproliferative neoplasms and the rational for targeting G6B, a protein expressed on platelets and megakaryocytes. Their pre-clinical work just earned Alethio an oral presentation at the upcoming ASH Annual Meeting.From Montreal: A panel of top venture investors who are based in Montreal discuss the state of biotech in the area and across Canada
04/11/2026 | 19 minSofinnova Investments' Maha Katabi, Finchley Healthcare Ventures' Pierre Beauparlant, and Amplitude Ventures' Jean-Francois Pariseau describe the biotech scene here, what Montreal and other Canadian biotech hubs do well, what could be improved, and the environment for entrepreneurs to turn ideas into companies.Abingdon, UK based T-Cypher Bio believes that the future of T-cell engagers will focus on intracellular targets - preclinical data on two novel targets, TC25 & TC11, will be at SITC
03/11/2026 | 11 minCEO Sarah Leonard describes the company's focus and process. The lead program, TC25, is scheduled to be in the clinic in 2028, and the company also has plans to go after auto-immune conditions in addition to oncology.After presenting data at ESMO this past weekend, Tango Therapeutics believes that adding PRMT5 to RAS inhibitors represents the 'next chapter' in today's pancreatic cancer revolution (and beyond)
29/10/2026 | 21 minPresident and CEO Malte Peters summarizes the ESMO data for vopemetistat, which was in second and third line pancreatic cancer in combination with daraxonrasib, and discusses plans for a phase 3 in first line (plus the regulatory path for later lines as well). Additionally, he discusses using PRMT5 inhibition in lung cancer and GBM.
Escucha BiotechTV - News, A hombros de gigantes y muchos más podcasts de todo el mundo con la aplicación de radio.es
Descarga la app gratuita: radio.es
- Añadir radios y podcasts a favoritos
- Transmisión por Wi-Fi y Bluetooth
- Carplay & Android Auto compatible
- Muchas otras funciones de la app
Descarga la app gratuita: radio.es
- Añadir radios y podcasts a favoritos
- Transmisión por Wi-Fi y Bluetooth
- Carplay & Android Auto compatible
- Muchas otras funciones de la app
BiotechTV - News
Descarga la app,
Escucha.
España
